- Home
- OVID vs ABOS Comparison
OVID vs ABOS Comparison
Compare OVID & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OVID | ABOS |
|---|---|---|
| Founded | 2014 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.5M | 113.9M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | OVID | ABOS |
|---|---|---|
| Price | $1.61 | $1.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $3.50 | ★ $7.67 |
| AVG Volume (30 Days) | ★ 1.6M | 211.7K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,610,000.00 | N/A |
| Revenue This Year | $1,077.56 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 945.89 | N/A |
| 52 Week Low | $0.24 | $0.86 |
| 52 Week High | $2.01 | $2.46 |
Technical Indicators
Market Signals| Indicator | OVID | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 48.35 | 51.88 |
| Support Level | $1.57 | $1.67 |
| Resistance Level | $1.65 | $2.39 |
| Average True Range (ATR) | 0.10 | 0.14 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 13.33 | 63.83 |
Price Performance
Historical ComparisonAbout OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.